EGFR
Los inhibidores del receptor del factor de crecimiento epidérmico (EGFR) son compuestos que bloquean la señalización del EGFR, un receptor que a menudo está sobreexpresado en varios tipos de cáncer y que juega un papel crucial en la angiogénesis. Los inhibidores del EGFR se utilizan para prevenir el crecimiento tumoral y las metástasis al interrumpir las vías que promueven la formación de vasos sanguíneos en los tumores. Estos inhibidores son ampliamente utilizados en la investigación y terapia contra el cáncer. En CymitQuimica, ofrecemos una amplia selección de inhibidores de EGFR de alta calidad para apoyar su investigación en oncología y angiogénesis.
Se han encontrado 582 productos de "EGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Andamertinib
CAS:Andamertinib is an EGFR inhibitor with antitumor activity.Fórmula:C31H36N8O3Forma y color:SolidPeso molecular:568.669ES-072
CAS:ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.Fórmula:C25H27F3N8O2Forma y color:SolidPeso molecular:528.53BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Fórmula:C29H33ClN8O4Forma y color:SolidPeso molecular:593.08EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Fórmula:C26H28ClN3O4Forma y color:SolidPeso molecular:481.97Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Fórmula:C24H24Br2ClN9O3Pureza:99.52%Forma y color:SolidPeso molecular:681.77Ref: TM-T13088
1mg133,00€5mg268,00€10mg409,00€25mg670,00€50mg888,00€100mg1.243,00€1mL*10mM (DMSO)414,00€HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Fórmula:C19H14BrF3N2OForma y color:SolidPeso molecular:423.23BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Fórmula:C18H15N3O2Forma y color:SolidPeso molecular:305.331EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Fórmula:C14H11BrN4O2SForma y color:SolidPeso molecular:379.23HER2-IN-21
CAS:HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.Fórmula:C20H18N4O3SForma y color:SolidPeso molecular:394.447EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Fórmula:C13H13N5OForma y color:SolidPeso molecular:255.275EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Fórmula:C15H12N2O4Forma y color:SolidPeso molecular:284.27EG31
CAS:EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Fórmula:C30H13Br2N3O6Forma y color:SolidPeso molecular:671.25JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Fórmula:C27H20N4O2SPureza:98%Forma y color:SolidPeso molecular:464.54HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Fórmula:C26H25F2N9O3Forma y color:SolidPeso molecular:549.53SORT1-IN-5
CAS:SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Fórmula:C19H31NO6SForma y color:SolidPeso molecular:401.52EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Forma y color:SolidHER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Fórmula:C17H18BrN5O2SForma y color:SolidPeso molecular:436.33PROTAC Her3-binding moiety 2
CAS:PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Fórmula:C25H25N7O2Forma y color:SolidPeso molecular:455.51EGFR Ligand-Linker Conjugates 1
CAS:EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Fórmula:C37H47N9O3Forma y color:SolidPeso molecular:665.83EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Fórmula:C27H19ClFN3OForma y color:SolidPeso molecular:455.91EGFR-IN-159
CAS:EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.Fórmula:C21H23N3O5Forma y color:SolidPeso molecular:397.424EGFR-IN-7
CAS:EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.
Fórmula:C32H41BrN9O2PPureza:95.32% - 99.64%Forma y color:SolidPeso molecular:694.6TLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFórmula:C16H15N5Forma y color:Yellow SolidPeso molecular:277.331HMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Forma y color:Odour LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Forma y color:Odour LiquidNimotuzumab (powder)
CAS:Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Forma y color:LiquidOlmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFórmula:C26H26N6O2SPureza:99.14%Forma y color:SolidPeso molecular:486.59Duligotuzumab
CAS:Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Pureza:95%Forma y color:LiquidRef: TM-T80604
Producto descatalogadoEGFR-IN-82
CAS:EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/
Fórmula:C32H41BrN9O2PPureza:98%Forma y color:SolidPeso molecular:694.6Ref: TM-T78788
Producto descatalogadoYK-029A
CAS:YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.
Fórmula:C27H32N8O2Pureza:98%Forma y color:SolidPeso molecular:500.6Ref: TM-T79461
Producto descatalogadoEGFR-IN-122
CAS:EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.
Fórmula:C19H20N4O3Forma y color:SolidPeso molecular:352.39Ref: TM-T200157
Producto descatalogadoEGFR-IN-123
CAS:EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.
Fórmula:C24H27F3N6OForma y color:SolidPeso molecular:472.51Ref: TM-T200485
Producto descatalogado
